This compound, known as CH5424802 (alectinib), is primarily utilized in the field of oncology research as a selective inhibitor of the Anaplastic Lymphoma Kinase (ALK) pathway, which is involved in cancer cell proliferation. It has shown promise in preclinical and clinical studies for its ability to inhibit the growth of certain types of cancer cells, particularly those driven by ALK genetic mutations or rearrangements. Researchers are exploring its potential as a therapeutic agent in treating cancers such as non-small cell lung cancer (NSCLC) and other ALK-driven malignancies. Additionally, it is being investigated for its efficacy in combination therapies to enhance the overall anti-tumor response and overcome resistance to existing treatments.